# Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

> **NCT00882414** · PHASE2 · TERMINATED · sponsor: **Vifor Pharma** · enrollment: 26 (actual)

## Conditions studied

- Thrombocytosis
- Iron-Deficiency Anemia

## Interventions

- **DRUG:** FERINJECT® (Ferric carboxymaltose)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00882414
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Main objective of study was met. Further recruitment was difficult.
- **Last updated:** 2010-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882414, "Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00882414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*